Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature
Tóm tắt
The 2014 WHO Classification of ovarian neoplasms introduced a new entity of seromucinous tumors associated with endometriosis. These tumors encompassed a spectrum from benign to malignant and included seromucinous cystadenoma/ cystadenofibroma, seromucinous borderline tumor/atypical proliferative seromucinous tumor and seromucinous carcinoma. However, the 2020 WHO Classification of Female Genital Tumours removed seromucinous carcinomas as a distinct entity and recategorized them as Endometrioid carcinomas with mucinous differentiation. Here we describe clinico-morphologic features of seromucinous tumors recategorizing cases originally diagnosed as seromucinous carcinoma in light of 2020 WHO classification and present detailed review of literature.
Ten cases were diagnosed. Mean age was 40 years. Four cases were bilateral. Mean size was 19 cm. Grossly; luminal papillary projections were seen in 6 cases. Tumors demonstrated a papillary architecture with papillae lined by stratified seromucinous epithelium showing nuclear atypia. Stromal invasion was seen in 4 cases. Six cases were reported as borderline seromucinous tumors and 4 cases originally diagnosed as seromucinous carcinoma were recategorized as endometrioid carcinoma with mucinous differentiation on review. Endometriosis was seen in 4 cases. CK7, PAX8 and ER were positive in 7/7 cases. Two cases showed extra-ovarian involvement. Follow up was available in 7 cases. Six patients were alive and well at follow up ranging from 8 to 46 months. Six patients received chemotherapy postoperatively. One patient with carcinoma died of disease 18 months postoperatively.
In our series, 4 cases were originally diagnosed as seromucinous carcinomas. However, these were recategorized in light of the 2020 WHO Classification of Female Genital tumors as endometrioid carcinomas with mucinous differentiation. Six cases were diagnosed as seromucinous borderline tumors. Thus, majority of cases were borderline in agreement with published literature.
Từ khóa
Tài liệu tham khảo
Kobel M, Bell DA, Carcangiu ML, Oliva E, Prat J, et al. Seromucinous tumors. Tumors of the Ovary. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumors of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2014. p. 38–40.
Frank GA, Moskvina LV, Andreeva YY. A new classification of ovarian tumors. Arkh Pathol. 2015;77(4):40–50. https://doi.org/10.17116/patol201577440-50.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26(12):1529–41. https://doi.org/10.1097/00000478-200212000-00001.
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J, Kommission Ovar of the AGO. Statement by the Kommission Ovar of the AGO: the new FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal Cancer. Geburtshilfe Frauenheilkd. 2015;75(10):1021–7. https://doi.org/10.1055/s-0035-1558079.
Kobel M, Kim K-R, McCluggage WL, Shih I, Single N. Seromucinous carcinoma. In: Cheung AN, Ellenson LH, Gilks CB, Kim K-R, Kong CS, Lax SF, Longacre TA, et al., editors. Tumors of ovary. In WHO Classification of Female Genital Tumors, vol. 70. 5th ed. Lyon: Edited by the WHO Classification of Tumors Editorial Board, International Agency for Research on Cancer (IARC); 2020.
Kobel M, Huntsman DG, Lim D, McCluggage WG, Rabban TT, Shih I. Endometrioid carcinoma of the ovary. In: Cheung AN, Ellenson LK, Gillks CB, Kim K-R, Kong CS, Lax SF, Longacre TA, et al., editors. Tumors of ovary. In WHO Classification of Female Genital Tumors. 5th ed. Lyon: Edited by the WHO Classification of Tumors Editorial Board, International Agency for Research on Cancer (IARC); 2020. p. 58–61.
Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised and expanded. Am J Pathol. 2016;186(4):733–47. https://doi.org/10.1016/j.ajpath.2015.11.011.
Wilbur MA, Shih Ie M, Segars JH, Fader AN. Cancer implications for patients with endometriosis. Semin Reprod Med. 2017;35(01):110–6. https://doi.org/10.1055/s-0036-1597120.
Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia. Pathology. 2018;50(2):190–204. https://doi.org/10.1016/j.pathol.2017.10.006.
Kurman RJ, Shih IM. Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol. 2016;35(1):78–81. https://doi.org/10.1097/PGP.0000000000000266.
Rambau PF, McIntyre JB, Taylor J, et al. Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol. 2017;41(5):685–95. https://doi.org/10.1097/PAS.0000000000000812.
Nagamine M, Mikami Y. Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues. Diagnostics (Basel). 2020;10:77. https://doi.org/10.3390/diagnostics10020077.
Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa T, Tsuda H, Furuya K. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis. J Gynecol Oncol. 2018;29(2):e20. https://doi.org/10.3802/jgo.2018.29.e20.
Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Ovarian atypical proliferative (borderline) mucinous tumors; gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25(1):83–9. https://doi.org/10.1097/01.pgp.0000177125.31046.fd.
Tang SX, Sun YH, Xu Y, Zhou XR, Yang WT. Clinicopathologic study of seromucinous carcinoma of the ovary. Zhonghua Bing Li Xue Za Zhi. 2016;45:774–9.
Rutgers JKL. Mullerian mucinous/mixed epithelial (Seromucinous) ovarian tumors. AJSP. 2016;21:206–13.
Karpathiou G, Chauleur C, Corsini T, Venet M, Habougit C, Honeyman F, Forest F, Peoc'h M. Seromucinous ovarian tumor. A comparison with the rest of ovarian epithelial tumors. Ann Diagn Pathol. 2017;27:28–33. https://doi.org/10.1016/j.anndiagpath.2017.01.002.
Han JW, Kim KA, Chang HY, Kim JW, Park YS, Lee J, Choi JW, Lee CH, Park CM. Newly categorized seromucinous tumor of the ovary: magnetic resonance imaging findings. J Comput Assist Tomogr. 2019;43(1):119–27. https://doi.org/10.1097/RCT.0000000000000776.
Kurata Y, Kido A, Moribata Y, Kameyama K, Himoto Y, Minamiguchi S, Konishi I, Togashi K. Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumor from endometriosis related malignant ovarian tumor. Eur Radiol. 2017;27(4):1695–703. https://doi.org/10.1007/s00330-016-4533-x.
Kurata Y, Kido A, Moribata Y, Kameyama K, Minamiguchi S, Konishi I, Togashi K. Differentiation of Seromucinous borderline tumor from serous borderline tumor on MR imaging. Magn Reson Med Sci. 2018;17(3):211–7. https://doi.org/10.2463/mrms.mp.2017-0055.
Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol. 2015;39(7):983–92. https://doi.org/10.1097/PAS.0000000000000405.
Nakamura E, Sato Y, Moriguchi S, Yamashita A, Higo T, Asada Y. Ovarian seromucinous borderline tumor and clear cell carcinoma: an unusual combination. Case Rep Obstet Gynecol. 2015;90891:1–5. https://doi.org/10.1155/2015/690891 Epub 2015 May 13.
Okumura T, Muronosono E, Tsubuku M, Terao Y, Takeda S, Maruyama M. Anaplastic carcinoma in ovarian seromucinous tumor of borderline malignancy. J Ovarian Res. 2018;11(1):77. https://doi.org/10.1186/s13048-018-0449-1.